Verde Science Inc. (VRCI) 0.2006 $VRCI
Verde Science Appoints International Banker Manfred A. Schauer
ACCESSWIRE - Mon Jun 01, 7:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 1, 2015 / (PINKSHEETS:VRCI) Verde Science Inc., a pharmaceutical research and development company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the appointment of Manfred Schauer as head of the Asia Pacific Region.
DB: 31.91 (+1.75)
Verde Science Adds Lawyer, Bradley J. Dixon, J.D. to Board
ACCESSWIRE - Wed May 20, 1:29PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2015 / Verde Science, Inc. (OTCPK: VRCI), a Pharmaceutical Research and Development Company focused on developing effective treatments for contemporary health issues, with an initial focus on developing cannabinoid-based prescription medicines is pleased to announce the appointment of Bradley J. Dixon, J.D. to its Board of Directors. Mr. Dixon is a partner with the firm of Stoel Rives, LLP, which has offices throughout the Northwest and California. His professional honors include selection as one of America's Leading Lawyers for Business by Chambers USA, listing in Mountain States Super Lawyers, and admission to the Order of Barristers. Mr. Dixon's areas of practice include Business Law, Government Affairs, Commercial Litigation, and Labor and Employment Law.
Verde Science Appoints New Chief Financial Officer with Pharmaceutical Sector Experience
ACCESSWIRE - Tue May 12, 5:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 12, 2015 / PINKSHEETS: VRCI Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions is pleased to announce the appointment of David Alexander, CA as its new CFO, effective immediately. David graduated with BComm in Finance from the University of British Columbia. He has managed the rapid growth of several early stage and startup companies. As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, and listed it on Nasdaq. Arakis was subsequently sold to Talisman Energy Inc. He was also CFO of Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical Research and Development Company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran subsequently, became into Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company (Nasdaq: CRME).
CRME: 8.65 (-0.11), TLM: 7.99 (unch)
Verde Science Adds John M. E. Percival to the Head of Strategic Development and Member of Board of Directors
ACCESSWIRE - Mon May 04, 5:04AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 4, 2015 / (PINKSHEETS: VRCI) Verde Science, Inc. a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions is pleased to announce the appointment of John M. E. Percival to its Board of Directors and Head of Strategic Business Development. Mr. Percival brings over 20 years of Investment Banking, Corporate Finance and Strategic planning success to Verde. Mr. Percival was previously General Manager of Investments at Barclays Bank New Zealand, Ltd where he was responsible for the management of nearly a $500 million in Superannuation and private funds.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part X
Anthony Cataldo - at Seeking Alpha - Tue Apr 21, 6:30AM CDT
XXII: 0.82 (+0.06), VPCO: 1.37 (-0.02)
Verde Science adds Shantesh Hede, Ph.D As Director of Product Development
ACCESSWIRE - Fri Apr 10, 7:15AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 10, 2015 / (PINKSHEETS:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the addition of Shantesh Hede, Ph.D. as Director of Product Development. Dr. Hede will be based in Mumbai, India and will direct Verde Science's R&D programs on-site with Verde's Research and Development partner, the Institute of Chemical Technology. He earned a Ph.D. in Bioengineering Systems from the MIT Portugal Program, a Master of Engineering Management from Duke University, and a Bachelors in Pharmaceutical Sciences from the Institute of Chemical Technology.
Verde Science Signs Research and Development Pact with Institute Of Chemical Technology
ACCESSWIRE - Wed Apr 08, 6:15PM CDT
LAS VEGAS, NV / ACCESSWIRE / April 8, 2015 / (PINKSHEETS: VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the execution of a definitive Research and Development Agreement with the Institute of Chemical Technology of Mumbai, India. Under the terms of the agreement Verde Science researchers and faculty and staff of the University will cooperate on original research with the goal of identifying and developing novel pharmaceutical formulations derived from the marijuana plant for the treatment of specific medical issues.
Verde Science Investor Update
ACCESSWIRE - Fri Mar 13, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 13, 2015 / Verde Science, Inc., (PINKSHEETS:VRCI) a Medical Research and Development Company focused on developing effective treatments for emerging and contemporary health issues, with an initial focus on Medical Marijuana is pleased to update shareholders and investors regarding significant developments in the Medical Marijuana R&D arena.
53 Marijuana Stocks - A Post-Mortem: Part III And Epilogue
Anthony Cataldo - at Seeking Alpha - Thu Mar 05, 2:25PM CST
VPCO: 1.37 (-0.02)
12 More Marijuana Stocks To Avoid - Part II
Anthony Cataldo - at Seeking Alpha - Thu Feb 19, 8:37AM CST
News Release Verde Science Pursuing Development of Promising Point-Of-Care Ebola Screening Test
ACCESSWIRE - Mon Nov 10, 8:08AM CST
Image: https://www.baystreet.ca/uploads/verde.jpg
Verde Science and Sterkem Group Sign Pharmaceutical Development Agreement
ACCESSWIRE - Thu Nov 06, 8:01AM CST
Image: https://www.baystreet.ca/uploads/eyukuVRCI.png
News Release Verde Science R
ACCESSWIRE - Tue Nov 04, 5:00AM CST
Verde Science R&D Team Ready To Move Forward With Design Of Research Plan
Verde Science Appoints Chief Technology Officer
ACCESSWIRE - Wed Oct 22, 8:03AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png
Verde Science Strengthens Scientific Team
ACCESSWIRE - Thu Oct 02, 8:01AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png
ID Global Corporation Seeks Strategic Partnership with Verde Science, Inc.
PR Newswire - Wed Oct 01, 9:47AM CDT
ID Global Corp. (OTC: IDGC) is pleased to announce that it has signed a binding Memorandum of Understanding (MOU) with Verde Science, Inc. (OTCBB:VRCI), a Medical Marijuana Research and Development Company with particular expertise in Aeroponic Growing Systems, to begin due-diligence towards a joint venture (Exclusive or non-exclusive) whereby IDGC will provide assistance in raising capital, business advisory services and/or merger discussions.
Verde Science Forms R and D Alliance
ACCESSWIRE - Tue Sep 23, 10:14AM CDT
Richmond, BC / ACCESSWIRE / September 23, 2014 / Verde Science, Inc., (OTCQB: VRCI) a Medical Marijuana Research and Development Company with particular expertise in Aeroponic Growing Systems for the production of pure, efficacious Medical Marajuana, is pleased to announce a Research and Development Alliance with a Mumbai, India based pharmaceutical company that has a record of significant success in the development of novel medical treatment compounds. This new relationship will allow Verde to launch immediately on its THC Pharmaceutical Development Program, and accelerate its R and D operations by about one year. Without this important alliance Verde would have experienced unnecessary delays as it waited for its Research and Development License in Canada. According to Harp Sangha, Verde's Chairman and CEO, "Now we can immediately access the vast treasure of our Indian partner's intellectual capital and tap into a highly educated organization of research scientists in a cost effective manner."
Verde Science to Present at Aegis Capital Conference
Newsfile Corp - Thu Sep 11, 11:08AM CDT
full story)
Verde Science Appoints International Banker Manfred A. Schauer
ACCESSWIRE - Mon Jun 01, 7:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 1, 2015 / (PINKSHEETS:VRCI) Verde Science Inc., a pharmaceutical research and development company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the appointment of Manfred Schauer as head of the Asia Pacific Region.
DB: 31.91 (+1.75)
Verde Science Adds Lawyer, Bradley J. Dixon, J.D. to Board
ACCESSWIRE - Wed May 20, 1:29PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2015 / Verde Science, Inc. (OTCPK: VRCI), a Pharmaceutical Research and Development Company focused on developing effective treatments for contemporary health issues, with an initial focus on developing cannabinoid-based prescription medicines is pleased to announce the appointment of Bradley J. Dixon, J.D. to its Board of Directors. Mr. Dixon is a partner with the firm of Stoel Rives, LLP, which has offices throughout the Northwest and California. His professional honors include selection as one of America's Leading Lawyers for Business by Chambers USA, listing in Mountain States Super Lawyers, and admission to the Order of Barristers. Mr. Dixon's areas of practice include Business Law, Government Affairs, Commercial Litigation, and Labor and Employment Law.
Verde Science Appoints New Chief Financial Officer with Pharmaceutical Sector Experience
ACCESSWIRE - Tue May 12, 5:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 12, 2015 / PINKSHEETS: VRCI Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions is pleased to announce the appointment of David Alexander, CA as its new CFO, effective immediately. David graduated with BComm in Finance from the University of British Columbia. He has managed the rapid growth of several early stage and startup companies. As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, and listed it on Nasdaq. Arakis was subsequently sold to Talisman Energy Inc. He was also CFO of Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical Research and Development Company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran subsequently, became into Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company (Nasdaq: CRME).
CRME: 8.65 (-0.11), TLM: 7.99 (unch)
Verde Science Adds John M. E. Percival to the Head of Strategic Development and Member of Board of Directors
ACCESSWIRE - Mon May 04, 5:04AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 4, 2015 / (PINKSHEETS: VRCI) Verde Science, Inc. a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions is pleased to announce the appointment of John M. E. Percival to its Board of Directors and Head of Strategic Business Development. Mr. Percival brings over 20 years of Investment Banking, Corporate Finance and Strategic planning success to Verde. Mr. Percival was previously General Manager of Investments at Barclays Bank New Zealand, Ltd where he was responsible for the management of nearly a $500 million in Superannuation and private funds.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part X
Anthony Cataldo - at Seeking Alpha - Tue Apr 21, 6:30AM CDT
XXII: 0.82 (+0.06), VPCO: 1.37 (-0.02)
Verde Science adds Shantesh Hede, Ph.D As Director of Product Development
ACCESSWIRE - Fri Apr 10, 7:15AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 10, 2015 / (PINKSHEETS:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the addition of Shantesh Hede, Ph.D. as Director of Product Development. Dr. Hede will be based in Mumbai, India and will direct Verde Science's R&D programs on-site with Verde's Research and Development partner, the Institute of Chemical Technology. He earned a Ph.D. in Bioengineering Systems from the MIT Portugal Program, a Master of Engineering Management from Duke University, and a Bachelors in Pharmaceutical Sciences from the Institute of Chemical Technology.
Verde Science Signs Research and Development Pact with Institute Of Chemical Technology
ACCESSWIRE - Wed Apr 08, 6:15PM CDT
LAS VEGAS, NV / ACCESSWIRE / April 8, 2015 / (PINKSHEETS: VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the execution of a definitive Research and Development Agreement with the Institute of Chemical Technology of Mumbai, India. Under the terms of the agreement Verde Science researchers and faculty and staff of the University will cooperate on original research with the goal of identifying and developing novel pharmaceutical formulations derived from the marijuana plant for the treatment of specific medical issues.
Verde Science Investor Update
ACCESSWIRE - Fri Mar 13, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 13, 2015 / Verde Science, Inc., (PINKSHEETS:VRCI) a Medical Research and Development Company focused on developing effective treatments for emerging and contemporary health issues, with an initial focus on Medical Marijuana is pleased to update shareholders and investors regarding significant developments in the Medical Marijuana R&D arena.
53 Marijuana Stocks - A Post-Mortem: Part III And Epilogue
Anthony Cataldo - at Seeking Alpha - Thu Mar 05, 2:25PM CST
VPCO: 1.37 (-0.02)
12 More Marijuana Stocks To Avoid - Part II
Anthony Cataldo - at Seeking Alpha - Thu Feb 19, 8:37AM CST
News Release Verde Science Pursuing Development of Promising Point-Of-Care Ebola Screening Test
ACCESSWIRE - Mon Nov 10, 8:08AM CST
Image: https://www.baystreet.ca/uploads/verde.jpg
Verde Science and Sterkem Group Sign Pharmaceutical Development Agreement
ACCESSWIRE - Thu Nov 06, 8:01AM CST
Image: https://www.baystreet.ca/uploads/eyukuVRCI.png
News Release Verde Science R
ACCESSWIRE - Tue Nov 04, 5:00AM CST
Verde Science R&D Team Ready To Move Forward With Design Of Research Plan
Verde Science Appoints Chief Technology Officer
ACCESSWIRE - Wed Oct 22, 8:03AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png
Verde Science Strengthens Scientific Team
ACCESSWIRE - Thu Oct 02, 8:01AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png
ID Global Corporation Seeks Strategic Partnership with Verde Science, Inc.
PR Newswire - Wed Oct 01, 9:47AM CDT
ID Global Corp. (OTC: IDGC) is pleased to announce that it has signed a binding Memorandum of Understanding (MOU) with Verde Science, Inc. (OTCBB:VRCI), a Medical Marijuana Research and Development Company with particular expertise in Aeroponic Growing Systems, to begin due-diligence towards a joint venture (Exclusive or non-exclusive) whereby IDGC will provide assistance in raising capital, business advisory services and/or merger discussions.
Verde Science Forms R and D Alliance
ACCESSWIRE - Tue Sep 23, 10:14AM CDT
Richmond, BC / ACCESSWIRE / September 23, 2014 / Verde Science, Inc., (OTCQB: VRCI) a Medical Marijuana Research and Development Company with particular expertise in Aeroponic Growing Systems for the production of pure, efficacious Medical Marajuana, is pleased to announce a Research and Development Alliance with a Mumbai, India based pharmaceutical company that has a record of significant success in the development of novel medical treatment compounds. This new relationship will allow Verde to launch immediately on its THC Pharmaceutical Development Program, and accelerate its R and D operations by about one year. Without this important alliance Verde would have experienced unnecessary delays as it waited for its Research and Development License in Canada. According to Harp Sangha, Verde's Chairman and CEO, "Now we can immediately access the vast treasure of our Indian partner's intellectual capital and tap into a highly educated organization of research scientists in a cost effective manner."
Verde Science to Present at Aegis Capital Conference
Newsfile Corp - Thu Sep 11, 11:08AM CDT
full story)
